The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Med.
Sec. Family Medicine and Primary Care
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1383112
This article is part of the Research Topic Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - Pathogenesis, Prevention and Treatment View all 6 articles
Development and pilot evaluation of an evidence-based algorithm for MASLD (formerly NAFLD) management in primary care in Europe
Provisionally accepted- 1 School of Medicine, University of Crete, Heraklion, Greece
- 2 Clinic of Social and Family Medicine, Department of Social Medicine, University of Crete, Heraklion, Greece
- 3 Kandanos Health Care Center, Chania, Greece
- 4 Independent researcher, Chania, Greece
- 5 Spilion Health Center, Rethymno, Greece
- 6 European Society for Primary Care Gastroenterology, Stockholm, Sweden
- 7 University Institute for Primary Care Research (IDIAP Jordi Gol), Barcelona, Spain
- 8 Independent researcher, Barcelona, Spain
- 9 Catalan Society of Family and Community Medicine, Barcelona, Balearic Islands, Spain
- 10 La LLagosta Primary Health Care Centre, Barcelona, Spain
- 11 Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- 12 Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, Netherlands
- 13 Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium
- 14 School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands, Netherlands
- 15 East Limburg Hospital, Genk, Belgium
- 16 Institute of Care and Public Health Research, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), emerges as major cause of morbidity and mortality globally, with chronic patients facing increased risk. Guidelines on MASLD management in primary care (PC) are limited. This study aimed to develop and evaluate a clinical care pathway for use in PC to improve MASLD screening and management, including early detection, communication and treatment, in three European countries (Greece, Spain, the Netherlands).Methods: An international multidisciplinary panel of experts oversaw pathway development, which was designed as a two-step algorithm with defined and sequenced tasks. To evaluate algorithm implementation, a controlled pilot study was conducted. Patients at risk of MASLD were assigned to general practitioners (GPs) trained in algorithm implementation (active group) or usual care (control group) and followed for 4-8 weeks. Primary outcomes were the number of patients screened for MASLD, managed in PC and referred to specialists.In this algorithm, patients with metabolic or liver dysfunction, confirmed MASLD or cardiovascular disease are screened with FIB-4 and classified as having risk of low-level (FIB-4<1.3), intermediate-level (1.3≤FIB-4<2.67) or high-level MASLD (FIB-4≥2.67). The algorithm provides evidence-based tools to support GPs manage patients with risk of low-level MASLD in PC, coordinate linkage of patients with risk of high-level MASLD to specialists and refer patients with risk of intermediate-level MASLD for elastography (low-risk if <7.9kPa or intermediate/high-risk if ≥7.9kPa). During pilot evaluation, N=37 participants were recruited in Spain (54.1% women, median age: 63 years). Significantly higher rates of patients in the active group (n=17) than the control group (n=20) were screened with FIB-4 (94.1% vs 5.5%, p=0.004). Patients in the active group received significantly more frequently a PC intervention for weight loss (70.6% vs 10.0%, p<0.001), alcohol regulation (52.9% vs 0%, p<0.001) and smoking cessation (29.4% vs 0%, p=0.005). In Greece no algorithm implementation was observed in either the active or control group, while the evaluation was not conducted in the Netherlands for logistic reasons.This study provides evidence on the development and implementation of a new PC algorithm for MASLD screening and management. Variations among participating settings in algorithm implementation are indicative of context-specific particularities.
Keywords: metabolic dysfunction-associated steatotic liver disease (MASLD), Primary Care, Clinical care pathways, Screening and management of diabetic foot patients, Risk classification
Received: 06 Feb 2024; Accepted: 04 Nov 2024.
Copyright: © 2024 Anastasaki, Papadakis, Gergianaki, Papastamatiou, Aligizakis, Grillaki, Boutzoukaki, Sivaropoulos, Anastasiou, Mendive, de Juan-Asenjo, Hernández-Ibáñez, Martínez-Escudé, Garcia-Retortillo, Koek, Heyens, Muris and Lionis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Marilena Anastasaki, School of Medicine, University of Crete, Heraklion, Greece
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.